Skip to main content
Advertising

Originally published Wednesday, November 20, 2013 at 6:58 AM

  • Share:
           
  • Comments (0)
  • Print

J&J to pay $2.5B to settle hip replacement suits

Johnson & Johnson said late Tuesday that it will pay $2.5 billion to settle thousands of lawsuits brought by hip replacement patients who accuse the company of selling faulty implants that led to injuries and additional surgeries.


Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

WASHINGTON —

Johnson & Johnson said late Tuesday that it will pay $2.5 billion to settle thousands of lawsuits brought by hip replacement patients who accuse the company of selling faulty implants that led to injuries and additional surgeries.

The agreement presented in U.S. District Court in Toledo, Ohio, is one of the largest for the medical device industry. It resolves an estimated 8,000 cases of patients who had to have the company's metal ball-and-socket hip implant removed or replaced. J&J pulled the implant from the market in 2010 after data showed it failed sooner than older implants.

The deal provides roughly $250,000 per patient and covers those who had their implants removed or replaced before Aug. 31 this year. The company expects to make most of the payments to patients in 2014.

At the court hearing was Richard Stark, of Erie, Mich., who said he received one of the all-metal implants five years ago and began feeling pain soon after the surgery.

"After the third year, I was in so much pain I couldn't take it," said Stark, who underwent another surgery in February to fix the implant. "The money's a bonus, but I'm happy my surgery worked out."

J&J's DePuy unit said in a statement that the deal does not cover all lawsuits pending against the company.

"DePuy will continue to defend against remaining claims and believes its actions related to the ASR Hip System have been appropriate and responsible," the company said.

The artificial hip, known as the Articular Surface Replacement, or ASR, was sold for eight years to some 35,000 people in the U.S. and more than 90,000 people worldwide. New Brunswick, N.J.-based J&J stopped making the product in 2009 and recalled it the next year.

However, internal J&J documents unsealed in the case suggest that company officials were aware of problems with the device at least as far back as 2008.

Also, according to a deposition from a J&J official, a 2011 company review of a patient registry concluded that more than one-third of the implants were expected to fail within five years of their implantation. Orthopedic hips are generally supposed to last at least 10 to 20 years.

The company's lawyers have denied that J&J acted improperly.

For decades nearly all orthopedic hips were coated with plastic or ceramic. But a decade ago many surgeons began to favor all-metal implants based on laboratory tests suggesting the devices would be more resistant to wear and reduce the chances of dislocation.

Recent data from patient registries show the devices actually fail at a higher rate than older implants, however. Last year a panel of government advisers said there are few, if any, cases where metal-on-metal hip implants should be recommended.

The pain and inflammation reported by patients implanted with the hips is usually caused by tiny metal particles that seep into the joint, damaging the surrounding tissue and bone.

DePuy said Tuesday it had already set aside funds to cover the settlement, which is not expected to affect future earnings.

The ASR recall is just one in an embarrassing string of J&J recalls stretching back to 2009, of products from contact lenses to prescription drugs and over-the-counter medicines.

Tuesday's settlement comes two weeks after another multibillion dollar J&J settlement involving the company's psychiatric drugs. The company said earlier this month it would pay $2.2 billion to settle Department of Justice allegations that J&J sales representatives used kickbacks and illegal marketing techniques to promote Risperdal for unapproved uses in children, the elderly and the mentally disabled.

___

Seewer reported from Toledo.



News where, when and how you want it

Email Icon

Meet the winemakers

Meet the winemakers

View video interviews, conducted by The Seattle Times wine writer Andy Perdue, profiling five of our state's top winemakers.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►